The United States biopsy devices market size reached US$ 901 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,118 Million by 2028, exhibiting a growth rate (CAGR) of 3.6% during 2023-2028. A significant rise in the prevalence of chronic diseases such as cancer, continuous technological advancements in biopsy guidance systems, favorable reimbursement policies, and the presence of a robust healthcare infrastructure in the United States are some of the major factors propelling the market growth.
|Market Size in 2022
||US$ 901 Million
|Market Forecast in 2028
||US$ 1,118 Million
|Market Growth Rate (2023-2028)
Biopsy devices are medical instruments designed to extract tissue or cell samples from various body parts for diagnostic purposes. These devices play a pivotal role in the early detection and diagnosis of cancer, infectious diseases, and other medical conditions. There are different types of biopsy devices, including fine-needle aspiration devices, core needle biopsy devices, and vacuum-assisted biopsy devices, each catering to specific diagnostic requirements. For instance, fine-needle aspiration devices are commonly used for sampling cells from organs like the thyroid or liver, whereas core needle biopsy devices are often used for extracting a 'core' of tissue from solid masses. These devices usually come with a specialized needle inserted into the body to retrieve the tissue sample under imaging guidance, such as ultrasound, MRI, or CT scans for precision. As a result, biopsy devices have gained immense traction among health professionals who rely on these tools to make accurate diagnoses, guide treatment plans, and improve patient outcomes.
The increasing prevalence of chronic diseases, such as cancer, will stimulate the growth of the biopsy devices market in the United States. Moreover, the presence of a robust healthcare infrastructure conducive to the adoption of advanced medical technologies is another major growth-inducing factor. The United States spends significantly on healthcare compared to other nations, creating an environment where high-quality diagnostic tools, like biopsy devices, can be readily integrated into the medical landscape. Additionally, favorable reimbursement policies often cover a portion of the costs associated with biopsy procedures, making it financially more accessible for a broader population to avail themselves of these diagnostic methods, accelerating the product adoption rate. In line with this, the country is home to numerous key players in the medical device industry who invest heavily in research and development (R&D). This creates a cycle of continuous innovation, ensuring that the market stays competitive and responsive to the evolving needs of healthcare providers and patients alike. Furthermore, the aging population in the region that is more susceptible to diseases requiring biopsies for diagnosis is propelling the market growth. As the number of people in older age brackets rises, there is a corresponding increase in the demand for diagnostic procedures, including biopsies, further driving market growth.
United States Biopsy Devices Market Trends/Drivers:
Rise in the Prevalence of Chronic Diseases
In recent years, the incidence of cancer has significantly escalated, making it one of the leading causes of death in the United States. This rise in the burden of chronic diseases necessitates effective diagnostic procedures to enable early detection and treatment. Biopsy procedures serve as a cornerstone in the diagnostic pathway for cancer and many other diseases, offering insights at the cellular or tissue level that other diagnostic methods cannot provide. The demand for biopsy devices increases owing to the growing number of cancer cases as medical professionals seek more accurate and rapid diagnostic solutions. This urgency has translated into sustained investment in the sector and increased procurement of biopsy devices by healthcare institutions. As a result, the need for early and accurate diagnosis, fueled by the high prevalence of chronic conditions, acts as a significant driving force behind the growth of the biopsy devices market in the United States.
Ongoing Advancements in Technology
Advancements in technology, particularly in automation and imaging guidance, are driving the market further. Emerging technologies are enhancing the capabilities of biopsy devices, making them more efficient, precise, and less invasive. Innovations such as real-time imaging guidance using ultrasound, MRI, or CT scans ensure higher accuracy during tissue sampling. This reduces the chances of repeat procedures and minimizes complications, improving patient outcomes. Moreover, the incorporation of automation in biopsy devices simplifies the procedure, making it more accessible for healthcare providers. These technological advancements bolster the effectiveness of biopsy procedures and elevate the confidence of medical practitioners in these diagnostic tools. As a result, healthcare institutions across the United States are increasingly adopting these advanced biopsy devices, fueling market growth.
United States Biopsy Devices Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the United States biopsy devices market report, along with forecasts at the country level from 2023-2028. Our report has categorized the market based on procedure type, product, application, guidance technique and end user.
Breakup by Procedure Type:
- Surgical Biopsy
- Needle Biopsy
Surgical biopsy accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the procedure type. This includes surgical biopsy and needle biopsy. According to the report, surgical biopsy represented the largest segment.
Surgical biopsy is often considered the gold standard for diagnosing various forms of cancer and other serious conditions, as it allows for the removal of a larger tissue sample. This provides a more comprehensive view of the cells and their architecture, facilitating a more accurate diagnosis. Besides this, the United States has a robust healthcare infrastructure with advanced surgical facilities, making surgical biopsies readily accessible to patients. Additionally, the favorable reimbursement environment encourages the use of surgical biopsy, as these procedures are often covered by insurance policies, reducing the financial burden on patients.
Furthermore, the expertise and specialization available in the United States healthcare system enable a higher rate of surgical biopsies. Also, surgical biopsy is frequently used in cases where other types of biopsies, such as fine-needle aspiration or core needle biopsy, may not be suitable or have produced inconclusive results. This adds an additional layer of utility, making surgical biopsy a versatile and trusted option for diagnosis, thereby contributing to the segment growth.
Breakup by Product:
- Biopsy Guidance Systems
- Needle Based Biopsy Guns
- Biopsy Needles
- Biopsy Forceps
Biopsy guidance systems hold the largest share in the industry
A detailed breakup and analysis of the market based on the product has also been provided in the report. This includes biopsy guidance systems, needle based biopsy guns, biopsy needles, biopsy forceps, and others. According to the report, biopsy guidance systems accounted for the largest market share.
Biopsy guidance systems enhance the accuracy and precision of biopsy procedures by providing real-time imaging guidance, which is crucial for targeting specific tissue samples. This high degree of accuracy minimizes the likelihood of repeated procedures and reduces potential complications, thus improving patient outcomes and experience. Moreover, the integration of advanced technologies like ultrasound, MRI, and CT scans in biopsy guidance systems offers an additional layer of reliability and efficacy, making them indispensable in modern healthcare settings. Moreover, the country’s robust healthcare is well-equipped to adopt and implement these technologically advanced systems.
Healthcare providers highly value the contribution of guidance systems in ensuring successful biopsy procedures and, consequently, accurate diagnoses. The existing favorable reimbursement landscape in the United States further incentivizes healthcare institutions to invest in high-quality biopsy guidance systems, as these systems often meet the criteria for insurance coverage. Besides this, biopsy guidance systems are often compatible with various types of biopsy devices, ranging from fine-needle to vacuum-assisted biopsies, making them versatile and widely applicable across different medical conditions and tissue types. This adaptability increases their market penetration, as they can be used in multiple healthcare scenarios, thus fostering segment growth.
Breakup by Application:
- Breast Biopsy
- Lung Biopsy
- Colorectal Biopsy
- Prostate Biopsy
Breast Biopsy represents the leading market segment
The report has provided a detailed breakup and analysis of the market based on the application. This includes breast biopsy, lung biopsy, colorectal biopsy, prostate biopsy, and others. According to the report, breast biopsy represented the largest segment.
Breast cancer is one of the most common cancers in the United States, especially among women. The high incidence rate necessitates frequent and early-stage biopsies to confirm or rule out malignancies. Early detection is vital for effective treatment, and breast biopsies offer a reliable diagnostic tool for this purpose. In addition, the heightened public awareness about breast cancer, partly due to advocacy, educational initiatives, and widespread screening programs like mammography, prompts more women to seek early diagnosis, thereby fueling the demand for breast biopsy procedures. Advanced imaging modalities like MRI, ultrasound, and mammography, often used in conjunction with biopsy guidance systems, have improved the precision of breast biopsies. This ensures that the most suspicious tissue is sampled, enhancing the procedure’s diagnostic accuracy.
The United States, with its state-of-the-art healthcare infrastructure, is particularly well-suited for the widespread adoption of these advanced technologies. Additionally, the reimbursement landscape in the United States favors the use of biopsy procedures for breast cancer detection. Many insurance plans cover the costs of these procedures, thus encouraging more women to undergo breast biopsies without the deterrence of financial burden. Apart from this, the presence of leading market players in the country, who continually innovate in this space, ensures that the most efficient and least invasive breast biopsy devices are readily available, thus propelling the segment growth.
Breakup by Guidance Technique:
- Ultrasound-guided Biopsy
- Stereotactic-guided Biopsy
- MRI-guided Biopsy
Ultrasound-guided Biopsy exhibits a clear dominance in the market
A detailed breakup and analysis of the market based on the guidance technique has also been provided in the report. This includes ultrasound-guided biopsy, stereotactic-guided biopsy, MRI-guided biopsy, and others. According to the report, ultrasound-guided biopsy accounted for the largest market share.
Ultrasound-guided biopsy is minimally invasive, reducing the risk of complications and speeding up patient recovery. This makes it a highly preferred option for both healthcare providers and patients. Also, the procedure is generally quicker and less expensive than other imaging-guided techniques such as MRI or CT scans, which plays a significant role in a healthcare environment that is highly cost-sensitive. Technological advancements have also contributed to its dominance. Modern ultrasound equipment offers high-resolution imaging, allowing for precise targeting of the tissue to be biopsied. This accuracy is crucial for ensuring that the most diagnostically useful sample is obtained, thereby improving the quality of diagnoses.
Moreover, ultrasound equipment is widely available in the United States and is often more accessible in various healthcare settings, including smaller or rural facilities, compared to more complex imaging systems like MRI machines. The flexibility of ultrasound-guided biopsy is another contributing factor. It is versatile and can be used for a range of tissue types and anatomical locations, including liver, kidney, and breast tissues, making it a highly adaptable diagnostic tool. Furthermore, the favorable reimbursement policies in the United States further accelerate the adoption of ultrasound-guided biopsy procedures. Many insurance plans recognize its diagnostic value and offer coverage, thus encouraging its use over other, more costly alternatives, supporting the segment growth.
Breakup by End User:
- Hospitals and Clinics
- Academic and Research Institutes
Hospitals and Clinics is the largest segment in the market
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals and clinics, academic and research institutes, and others. According to the report, hospitals and clinics represented the largest segment.
Hospitals and clinics are often the primary settings where advanced diagnostic procedures, including biopsies, are performed. They have the necessary infrastructure, ranging from state-of-the-art imaging equipment to specialized surgical facilities, which allows them to offer a broad range of biopsy methods. This comprehensive capability makes them a preferred choice for patients requiring biopsy procedures. Moreover, hospitals and clinics benefit from a multidisciplinary approach to patient care, with ready access to pathologists, radiologists, and specialists in various fields. This promotes effective and rapid diagnosis, enhancing the utility of biopsy devices in these settings. The availability of skilled medical personnel also ensures that biopsies are conducted under highly controlled conditions, which is crucial for the accuracy and reliability of the procedure.
Additionally, hospitals and clinics in the United States are more likely to receive insurance reimbursements for biopsy procedures, given their established record-keeping and compliance with healthcare regulations. The favorable reimbursement landscape encourages more patients to opt for biopsies within these settings, thus driving demand for biopsy devices. Along with this, hospitals and clinics are more accessible for the majority of the population, offering both emergency and scheduled healthcare services. This accessibility further boosts the number of biopsy procedures in these facilities, contributing to their leading market share. Besides this, the presence of in-house pathology labs in many hospitals and clinics enables quick turnaround times for biopsy results, which is a significant factor for patients and healthcare providers alike in urgent diagnostic scenarios, thereby catalyzing segment growth.
Breakup by Region:
South exhibits a clear dominance in the market
The report has also provided a comprehensive analysis of all the major regional markets, which include Northeast, Midwest, South, and West. According to the report, South was the largest market for United States biopsy devices in the country.
South held the biggest share in the United States biopsy devices market since the region has a high population density and a diverse demographic makeup, leading to a higher prevalence of diseases that require biopsy for diagnosis, such as cancer. In addition, the South is home to several major cities and healthcare hubs equipped with advanced medical facilities, including state-of-the-art hospitals and specialized clinics. These healthcare institutions have the necessary infrastructure to adopt and utilize sophisticated biopsy devices, thereby driving the market. The region also benefits from a network of renowned academic and research institutions that focus on medical research and innovation. These organizations often collaborate with healthcare providers, spurring the adoption of cutting-edge biopsy technologies and methodologies.
Another major contributing aspect is the availability of favorable insurance and healthcare policies, which make biopsy procedures more accessible and affordable to a broader range of people. The South region is witnessing significant healthcare investment both from the public and private sectors, which aids in the procurement of advanced medical devices, including biopsy devices. Furthermore, the extensive reach of healthcare services in the South, including in rural and underserved areas, fuels the uptake of biopsy devices. These areas often rely on larger healthcare hubs for advanced diagnostic services, which include biopsy procedures, positioning South as a leading regional market for biopsy devices in the United States.
The market is experiencing moderate growth as key players are actively engaging in various strategies to maintain and enhance their market position. They are heavily investing in research and development (R&D) to create more advanced, efficient, and less invasive biopsy devices. Innovations often focus on improving accuracy, minimizing discomfort, and speeding up the diagnostic process. The development of new technologies, such as real-time imaging guidance systems, is a significant area of investment. Another critical strategy is mergers and acquisitions. Companies are strategically acquiring or partnering with other firms, including technology startups and specialized medical device companies, to expand their product portfolios and reach. This consolidation allows them to offer a more comprehensive range of biopsy solutions and strengthens their competitive edge. Furthermore, industry leaders are also concentrating on regulatory approvals to ensure their products meet the strict quality and safety standards set by healthcare authorities. Gaining approval from agencies like the U.S. Food and Drug Administration (FDA) lends credibility and facilitates the adoption of their devices in healthcare institutions. These leaders are also focusing on product launches to introduce new biopsy devices to the market, aiming to meet the evolving needs of healthcare providers and patients. These launches are often supported by robust marketing campaigns to increase product awareness and adoption rates. Additionally, players in the market are enhancing their distribution networks to ensure that their products are readily available across various healthcare settings, including hospitals, clinics, and diagnostic centers. They are often working with healthcare providers to offer training and support, ensuring that medical staff are well-equipped to use the new technologies effectively. Moreover, customer engagement and after-sales service are increasingly becoming focal points as providing timely maintenance, training, and customer support is crucial for retaining market share and building long-term relationships with healthcare institutions.
The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
United States Biopsy Devices Market Report Scope:
|Base Year of the Analysis
Scope of the Report
Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
- Procedure Type
- Guidance Technique
- End User
|Procedure Types Covered
||Surgical Biopsy, Needle Biopsy
||Biopsy Guidance Systems, Needle Based Biopsy Guns, Biopsy Needles, Biopsy Forceps, Others
||Breast Biopsy, Lung Biopsy, Colorectal Biopsy, Prostate Biopsy, Others
|Guidance Techniques Covered
||Ultrasound-guided Biopsy, Stereotactic-guided Biopsy, MRI-guided Biopsy, Others
|End Users Covered
||Hospitals and Clinics, Academic and Research Institutes, Others
||Northeast, Midwest, South, West
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report:
- How has the United States biopsy devices market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the United States biopsy devices market?
- What is the impact of each driver, restraint, and opportunity on the United States biopsy devices market?
- What is the breakup of the market based on the procedure type?
- Which is the most attractive procedure type in the United States biopsy devices market?
- What is the breakup of the market based on the product?
- Which is the most attractive product in the United States biopsy devices market?
- What is the breakup of the market based on the application?
- Which is the most attractive application in the United States biopsy devices market?
- What is the breakup of the market based on the guidance technique?
- Which is the most attractive guidance technique in the United States biopsy devices market?
- What is the breakup of the market based on the end user?
- Which is the most attractive end user in the United States biopsy devices market?
- What is the competitive structure of the United States biopsy devices market?
- Who are the key players/companies in the United States biopsy devices market?
Key Benefits for Stakeholders:
- IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the United States biopsy devices market from 2017-2028.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the United States biopsy devices market.
- Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the United States biopsy devices industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.